尊龙凯时人生就是搏!(中国)官方直营

Dear Colleagues,

As we bid farewell to the old year and welcome the new, I am honored to extend, on behalf of the board and shareholders of New Frontier Health/United Family Healthcare, the sincerest greetings and best wishes for the Year of the Snake!

Time marches on, and memories linger. In 2024, we found ourselves in a time full of both challenges and opportunities. The uncertainty in the economic environment has put pressure on premium healthcare services, while an increasing number of high-quality medical institutions are entering the market, intensifying competition. At the same time, China’s demographic structure is undergoing profound changes with our rapidly aging population. This trend has not only led to a sharp increase in healthcare demands but also presented us with tremendous opportunities to develop new therapeutic areas and innovate our care delivery model. From chronic disease management to cancer treatment, from cardiovascular to neurological conditions, from clinics to homes, the aging society is challenging us to innovate and upgrade our capabilities. Only by consistently maintaining a high level of clinical expertise, strengthening service safety & quality and efficiency, and collaborating closely as a united team can we seize opportunities amidst challenges and stand out in this competitive market.

Despite the uncertainties in the external environment, in 2024, New Frontier Health (including United Family Healthcare, Heal Medical, and Hong Kong Integrated Oncology Center) achieved commendable results. This year, we served over one million patient visits, representing an 11% growth compared to 2023. The number of inpatient admissions reached approximately 20,000, a nearly 30% increase from 2023, and the total number of surgeries performed was approximately 11,000, with about 50% being grade 3/4 surgeries. The overall surgery volume increased by 49%, while the volume of grade 3 and 4 surgeries grew by 55%. Behind these numbers are the hopes of patients and their families, as well as the unwavering commitment of every New Frontier Health and United Family medical staff member and employee who strives to do their utmost to meet these hopes.

In 2024, we continuously strengthened our clinical medical capabilities. At Beijing United Family Hospital, the Department of Gastroenterology successfully implemented an ERCP procedure to remove a papillary adenoma of the duodenal papilla for a patient, while the Neurology and Neurosurgery Center successfully implanted a brain pacemaker with sensory function for another patient. In Guangzhou United Family Hospital, a series of surgeries were successfully conducted for a child with clubfoot, enabling her to take her first step in life. We helped a 62-year-old patient regain vitality through atrial fibrillation cryoablation, and we gave a 28-week premature baby a chance to see the world. We removed a 22-kilogram ovarian cyst that had troubled a 70-year-old patient for 20 years, and we operated on a child with a 90-degree spinal curvature. We added our 2nd and 3rd state-of-the-art da Vinci surgical systems as the number of robotic surgeries surpassed 1,000, making us the leader in terms of volume among private hospitals nationwide.

In 2024, we provided medical services to nearly 200,000 foreign patients. In Shanghai, we successfully treated a British patient suffering from massive gastrointestinal bleeding. The patient was in critical condition twice within 48 hours, with nearly 20 doctors involved in the rescue effort, administering a total of 8,000 milliliters of blood transfusion. An 84-year-old Swedish patient, who suffered a femoral neck fracture after a fall while traveling in Shanghai, was swiftly provided with a multidisciplinary and multilingual medical team. We safely conducted the surgery and offered meticulous care until the patient fully recovered and returned to Sweden. In Guangzhou, we successfully treated a foreign friend who suffered a myocardial infarction during the Canton Fair. Our United Family Healthcare’s multilingual and multidisciplinary team has been dedicated to serving the expatriate community, contributing to China’s efforts to improve the business environment.

In 2024, our Greater Bay Area health system continued to develop. In May, New Frontier Group completed the acquisition of Hong Kong Integrated Oncology Centre, a leading comprehensive private oncology medical platform. This strategic move has established New Frontier as the sole health system with presence in Hong Kong and all tier 1 cities in mainland China. We are now well-positioned to provide high-quality integrated medical services, encompassing cutting-edge oncology care, to patients across the entire Greater Bay Area. Shenzhen United Family Hospital became the implementation site for the Special Administrative Region's "Elderly Medical Voucher Pilot Program in the Greater Bay Area," provided over 8,500 outpatient services to more than 4,000 Hong Kong patients in 2024. Surgery volume increased nearly sixfold compared to the previous year. Guangzhou and Shenzhen United Family Hospitals successfully reached a direct payment agreement with Prudential Hong Kong, the first direct payment cooperation with a Hong Kong insurance company in our network. Meanwhile, The Guangzhou and Shenzhen United Family Hospitals have realized cross-border referral services with Heal Medical and the Hong Kong Integrated Oncology Cancer Center.

Leveraging the policy of the "Hong Kong and Macao Drug and Medical Device Transit" at GZU and SZU, we introduced innovative drugs and medical devices into mainland China, with more than 16 types of innovative drugs being implemented, benefiting over 1,600 patients.

The integrated development of medical practice, research, and education is the cornerstone of solidifying clinical capabilities. New Frontiers Health/United Family Healthcare has always been committed to supporting our medical team in their academic pursuits. In 2024, a total of 42 medical staff members were promoted to senior professional titles, and the number of SCI papers published by first authors and corresponding authors increased by 12% year-on-year, 62 doctors have published papers in distinguished domestic and international journals, with several of them successfully obtaining patents. marking a significant enhancement in academic and research capabilities. Additionally, we organized 10 large-scale professional academic conferences and actively engaged in cutting-edge domestic and international disciplinary research. In terms of teaching and training, we have established close cooperation with the medical schools of several renowned universities, including Capital Medical University, Tsinghua University, Jinan University, Tongji University, The University of Hong Kong, and The Chinese University of Hong Kong, greatly improving the clinical teaching abilities of our medical personnel. Furthermore, we held two nationwide problem-based learning (PBL) general medicine training sessions, attracting community doctors from more than 10 provinces and cities across the country. By providing higher-quality medical services to local communities and contributing to "Healthy China," we are making a positive impact.

In 2023, when we announced that we would actively embraced AI as one of our core strategies. In 2024, our self-developed Chinese English AI translation model tripled the translation accuracy rate, with a total of 1.3 million queries since its launch. The CPT search system reduced single-case query time by 75%, while our pioneering intelligent physician workstation, through in-depth data governance and large model technology, increased physicians' case-search efficiency by 400%. To make the patient journey more intelligent, we continuously optimized the user experience of the patient mini app, providing over 500,000 appointment services for clients. The new SCRM system shortened response times by 70%, significantly enhancing patient experience. We are also proud of our commitment to corporate social responsibility in 2024. A total of 76 medical staff members participated in medical public welfare activities organized by the United Foundation for China’s Health, providing timely and effective medical assistance to over 4,500 people in need.

I want to take this opportunity to share with you our strategic vision. Together, we have built a legacy of excellence in premium healthcare, and our ambition now is to elevate this legacy to new heights.

Our vision is clear: To become one of the most respected and leading private healthcare systems in China and beyond.

With the large-scale development of new hospitals across the nation over the past few years, and the continued growth of our Hong Kong footprint—including HKIOC and HEAL—we now offer a comprehensive continuum of care, spanning from primary to tertiary care. This system of 11 hospitals, 5 cancer centres and nationwide clinics network across key regions—Beijing, Tianjin, Shanghai, Guangzhou, Shenzhen, and Hong Kong—provides us with an unparalleled platform to lead and innovate.

Our journey forward will be guided by six key strategies, each designed to position us for sustained growth, deeper impact, and lasting leadership in China and beyond.

1. Building Comprehensive Health System Nationwide and Maintaining Leadership Position in Our Core Regions

We will establish New Frontier Health / UFH as the leading nationwide comprehensive healthcare system with leadership positions in each of our key markets across Beijing-Tianjin, Shanghai, and the Greater Bay Area (GBA).

• Beijing-Tianjin Area – Comprehensive, Multi-Tiered Expansion Currently operating five hospitals, and with Beijing United Family International Hospital (BJU 2.0) in development, our BTA system will adopt a vertically integrated, tiered service model covering general and specialty hospitals, as well as specialized cancer center and clinics network. BJU 2.0 is poised to become our flagship tertiary comprehensive hospital, boasting advanced surgical capabilities and integrating clinical research with specialized development in oncology, neurology, and cardiovascular care. Our main Jiangtai campus and Datun campus are gradually maturing into a robust tertiary hospitals; After installation of the latest Da Vinci Surgical System, DCU will introduce a new multi-payor system (after being admitted into the Basic Medical Insurance reimbursement program) and invest in nuclear medicine as part of its core service offering, and ultimately upgrade to a tertiary hospital.
• Shanghai Area—— Consolidating Foundations for Growth Our Shanghai Area system will commit to building a robust medical system, enhancing medical and operational capabilities. This includes strengthening the core hospital functions, streamlining patient care processes, and improving operational efficiency to ensure sustainable development and competitive differentiation. Our Changing hospital will leverage its new Da Vinci Surgical System and will further develop comprehensive internal medicine, surgery, orthopedics / sports medicine, and oncology capabilities. The Jing'an hospital is dedicated to becoming one of the leading private medical institutions in downtown Shanghai in terms of comprehensive service offerings and quality. The Pudong Hospital will introduce a multi-payor system (introducing basic medical insurance reimbursement) and upgrade its medical service capabilities, including the introduction of nuclear medicine services.
• The Greater Bay Area (GBA) —— Cross-border Integration Our GBA Area system aspires to become a hub for cross-border medical services, connecting Guangdong's superior medical resources with Hong Kong's significant private health and insurance market. Shenzhen and Guangzhou United Family Hospitals will continue to develop into tertiary hospitals specializing in women's health, children's health, oncology, orthopedics/sports medicine, cardiovascular diseases and neurology, servicing patients from Hong Kong and southern China. By collaborating with insurance companies, Hong Kong residents will be able to seek medical treatment in Shenzhen and the GBA. Heal Medical and the HKIOC will continue to leverage Hong Kong's unique position as a special zone for accessing the latest global innovative drugs, providing the most cutting-edge treatment options for patients in Hong Kong, mainland China, and around the world.

Develop Integrated Cancer Care, and Establish Our Research Platform

• Oncology as the Group Core Strategy – We will develop a national oncology platform across all markets, focusing on multidisciplinary collaboration to provide comprehensive cancer care. The platform will bring together surgical, medical, and radiation oncologists, along with radiologists and supportive care teams, ensuring seamless, patient-centered treatment. We will invest in developing COEs around lung, breast, gynecological, urological and other cancer types.
• Establish Platform for Research and Clinical Trials – We will participate in more clinical trials and obtain Good Clinical Practice (GCP) certification across our major regions, positioning us as a trusted partner for pharmaceutical companies and international research initiatives. This will open opportunities to conduct clinical trials and bring new treatments to clinics, benefiting patients and elevating our reputation in medical innovation.

3. Simplify Our Management Structure and Enhance Our Talent Pipeline

With our rapid growth from 5 hospitals five years ago to 11 hospitals, 5 cancer centers and a nationwide clinics network today, the complexity of managing operations across multiple markets has increased significantly. To support this expansion, we will adopt a more effective management model that enhances coordination between headquarters and markets, while fostering greater collaboration among hospitals within the same market.

• Market Coordination and Hospital Networks – we will strengthen market coordination to ensure hospitals within the group share resources, streamline operations, and align clinical pathways. While individual hospitals will continue to adapt to local market needs, greater collaboration across facilities will drive efficiency and quality in care delivery.
• Enhanced Central Oversight and Governance – UFH headquarters will reinforce its focus on strategic planning, financial control, talent development, quality and safety, standard setting, and technology development to provide support and guidance to our frontline colleagues and further streamline and integrate the back-office functions of the headquarters and the markets.– We will participate in more clinical trials and obtain Good Clinical Practice (GCP) certification across our major regions, positioning us as a trusted partner for pharmaceutical companies and international research initiatives. This will open opportunities to conduct clinical trials and bring new treatments to clinics, benefiting patients and elevating our reputation in medical innovation.
• Enhance management efficiency: The headquarters and the markets will simplify management levels and streamline reporting lines and approval system to improve management efficiency.
• Continue to develop our talent pipeline

4. Reaffirm Our Patient Centric Culture

We will reaffirm our core value of patient centric care.

• Strengthening Patient-Centered Values – we will reaffirm our patient-first philosophy by embedding compassion, quality, and trust into daily operations and decision-making. This focus will shape clinical protocols, staff development, and leadership practices, ensuring that exceptional patient care remains the foundation of our identity across all hospitals and clinics.
• Establish Group Patient Experience Function – to support our facilities in training, measuring and upgrading our patient service capabilities. We also look to bring in standard operating procedures and technology innovation to future enhance our industry leading patient experience.
• Driving Excellence and Accountability – We will continue to foster a culture of continuous improvement and results-driven performance, pushing teams to set higher benchmarks in clinical care, operational efficiency, and innovation. By reinforcing ownership and accountability at all levels, we will ensure that striving for excellence is a shared responsibility across the organization.
• Embedding Collaboration Across Teams – We will build a culture where collaboration is ingrained in daily operations, starting within each hospital, strengthening coordination across hospitals and markets. By promoting open communication, joint problem-solving, and shared initiatives, we will enhance teamwork and break down silos to drive innovation, efficiency, and improved patient outcomes.

5. Technology, Digital, and Innovation

Technology will drive our growth by enhancing operational efficiency, improving patient convenience, and elevating clinical quality.

• AI and Data for Operational and Clinical Excellence – we will leverage AI and big data to improve hospital management, streamline workflows, and enhance decision-making, driving efficiency across our operations. Predictive analytics and AI-powered digital tools will support physicians in diagnostics and treatment planning, support nurses in providing seamless care from hospital to clinics to home, reducing variability and enhancing the quality of care, while also optimizing resource allocation.
• Digital Ecosystem and Patient Connectivity – we will build a connected digital ecosystem that integrates patient data from hospital to home, enabling seamless transitions and continuous care. By collaborating other sister companies within New Frontier, we will develop smart health solutions that enhance patient convenience through real-time access to medical records, personalized health management tools, and streamlined billing processes.

6. Strengthen Our Global Connectivity and Our Leading Position in International Healthcare

• Global Partnerships and Joint Treatment Networks – We will further expand our global partnerships with leading institutions such as Mayo Clinic and HSS, creating joint clinical, academic and research partnerships. The newly established United Family International Medical Service (IMS) works with global leading hospitals to provide joint international treatment options. IMS will also leverage China’s innovation in medicines and medical devices, as well as cost effective treatment cost, to attract patients to China.
• International Medical Services – We will strengthen our position as the leading healthcare provider for expatriates, diplomats, and international business leaders in China. By expanding tailored services, embassy collaborations, and partnerships with multinational corporations, we will further solidify our reputation as the preferred destination for high-end international healthcare.

These six strategies form the foundation of our shared future. They are ambitious, but they reflect the capabilities, values, and vision of this exceptional organization. Together, we will redefine healthcare in China, Asia, and beyond, setting new benchmarks for excellence and innovation.

I am deeply grateful for the dedication and talent each of you brings to this organization. It is my honor to work with such a talented and committed group of colleagues and I am committed to support you, so that we can together help address some of the most pressing challenges and opportunities in healthcare in China in the years to come.

Thank you for your hard work and unwavering commitment to our vision.

Lastly, I hope we will continue to do good and do well, with love.

Wish you all a very happy year of snake.

Carl